Suggested remit: To appraise the clinical and cost effectiveness of pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6397
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 14 January 2026 - 11 February 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 14 October 2024 | Note - Note added to the project documents |
| 08 August 2024 | Note - Note added to the project documents |
| 14 February 2024 | In progress. Scoping commenced. |
| 30 January 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 30 January 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual